We are analyzing https://link.springer.com/article/10.1007/s00432-023-04604-6.

Title:
Antitumor activity of triazine mimic antibiotics for DNA-binding implications (impressive activity in vitro against a variety of tumor types in the NCI-60 screen): NSC 710607 to fight HCT-116 human colon carcinoma cell lines in vivo using the hollow fiber assay and xenograft mouse models | Journal of Cancer Research and Clinical Oncology
Description:
Purpose Successful clinical applications of DNA-directed selective cytotoxic agents disrupt the vital replication/transcription processes and ultimately lead to cancer cell death. This study aimed to examine the growth screen of two lead triazine compounds in a number of cell lines and xenografts and to develop anticancer agents with noncovalent binding affinity bringing fewer side effects. Methods The NCI initial hollow fiber test was performed using an established procedure. The cytostatic and cytocidal capacities of the test compounds were assessed by evaluating cytotoxicity by simply performing a standard cellular viability assay. The nude mouse human tumor xenograft system was used as an in vivo model. Results More sensitive drug with sub-micromolar activity met the interdisciplinary criteria for testing and was referred to evaluations in subcutaneous colorectal carcinoma HCT-116 human tumor xenografted into nude mice. Principal findings of the study: total cytostasis, almost nontoxic schedules, specific working hypotheses, strong rationale for the potential use, and important general implications (relevance to human biology). NSC 710607 displayed in vivo better than Cisplatin and 5-fluorouracil abilities to significantly decrease tumor growth. Conclusion Cell proliferation can be reduced or stopped in vivo in view of the xenograft results. The mimic molecule behaves as DNA-binding antitumor antibiotics with great potential as general anticancer agents and deserves further trials. NSC 710607 represents the result of a design strategy with outstanding potential. This study also identifies the prognostic significance and is likely to translate to other species or systems.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Technology & Computing
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

article, google, scholar, pubmed, cas, cancer, dna, anticancer, agents, spychala, human, chem, activity, synthesis, med, central, author, research, antitumor, nci, cell, binding, drug, colorectal, access, res, data, vivo, study, design, privacy, cookies, content, journal, publish, implications, tumor, hct, carcinoma, hollow, fiber, assay, xenograft, mouse, potential, httpsdoiorg, springer, information, search, clinical,

Topics {✒️}

month download article/chapter rna-specific groove-binding cations cyclic-aminotropiminium carboxylate derivatives anti-pneumocystis carinii agents covalent ligand/dna interactions hollow fiber assay dna-binding antitumor antibiotics writing—original draft preparation eortc/nci worldwide activity tri-functional mononuclear platinum vital replication/transcription processes cytotoxic anticancer effects human dna topoisomerase dna binding agents full article pdf dna binding levels dna minor groove accepted manuscript version xenograft mouse models privacy choices/manage cookies cancer cell death clinical oncology aims related subjects xenografted pc3 tumors van krieken jh develop anticancer agents dna-binding implications colorectal cancer survival double stranded dna dna-topoisomerase inhibitors target dna recognition general anticancer agents crispr-cas12c1 system cell lines article spychala dna topoisomerase ii specific working hypotheses nucleic acids res jaroslaw spychala antiviral drug design anticancer efficacy studies triazine mimic antibiotics holds exclusive rights xenograft data provided micromolar activity met promising antitumor activity european economic area mimic molecule behaves molecular docking studies substituted 4-oxothiazolidin-3-yl

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Antitumor activity of triazine mimic antibiotics for DNA-binding implications (impressive activity in vitro against a variety of tumor types in the NCI-60 screen): NSC 710607 to fight HCT-116 human colon carcinoma cell lines in vivo using the hollow fiber assay and xenograft mouse models
         description:Successful clinical applications of DNA-directed selective cytotoxic agents disrupt the vital replication/transcription processes and ultimately lead to cancer cell death. This study aimed to examine the growth screen of two lead triazine compounds in a number of cell lines and xenografts and to develop anticancer agents with noncovalent binding affinity bringing fewer side effects. The NCI initial hollow fiber test was performed using an established procedure. The cytostatic and cytocidal capacities of the test compounds were assessed by evaluating cytotoxicity by simply performing a standard cellular viability assay. The nude mouse human tumor xenograft system was used as an in vivo model. More sensitive drug with sub-micromolar activity met the interdisciplinary criteria for testing and was referred to evaluations in subcutaneous colorectal carcinoma HCT-116 human tumor xenografted into nude mice. Principal findings of the study: total cytostasis, almost nontoxic schedules, specific working hypotheses, strong rationale for the potential use, and important general implications (relevance to human biology). NSC 710607 displayed in vivo better than Cisplatin and 5-fluorouracil abilities to significantly decrease tumor growth. Cell proliferation can be reduced or stopped in vivo in view of the xenograft results. The mimic molecule behaves as DNA-binding antitumor antibiotics with great potential as general anticancer agents and deserves further trials. NSC 710607 represents the result of a design strategy with outstanding potential. This study also identifies the prognostic significance and is likely to translate to other species or systems.
         datePublished:2023-02-13T00:00:00Z
         dateModified:2023-02-13T00:00:00Z
         pageStart:6501
         pageEnd:6511
         sameAs:https://doi.org/10.1007/s00432-023-04604-6
         keywords:
            HCT-116 colorectal carcinoma
            Hollow fiber assay
            Large-scale NCI-60
            Mechanisms of cancer
            Mouse xenografts
            MV-3 human melanoma
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig6_HTML.png
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:149
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jaroslaw Spychala
               url:http://orcid.org/0000-0002-9965-2425
               affiliation:
                     name:
                     address:
                        name:Poznan, Poland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Antitumor activity of triazine mimic antibiotics for DNA-binding implications (impressive activity in vitro against a variety of tumor types in the NCI-60 screen): NSC 710607 to fight HCT-116 human colon carcinoma cell lines in vivo using the hollow fiber assay and xenograft mouse models
      description:Successful clinical applications of DNA-directed selective cytotoxic agents disrupt the vital replication/transcription processes and ultimately lead to cancer cell death. This study aimed to examine the growth screen of two lead triazine compounds in a number of cell lines and xenografts and to develop anticancer agents with noncovalent binding affinity bringing fewer side effects. The NCI initial hollow fiber test was performed using an established procedure. The cytostatic and cytocidal capacities of the test compounds were assessed by evaluating cytotoxicity by simply performing a standard cellular viability assay. The nude mouse human tumor xenograft system was used as an in vivo model. More sensitive drug with sub-micromolar activity met the interdisciplinary criteria for testing and was referred to evaluations in subcutaneous colorectal carcinoma HCT-116 human tumor xenografted into nude mice. Principal findings of the study: total cytostasis, almost nontoxic schedules, specific working hypotheses, strong rationale for the potential use, and important general implications (relevance to human biology). NSC 710607 displayed in vivo better than Cisplatin and 5-fluorouracil abilities to significantly decrease tumor growth. Cell proliferation can be reduced or stopped in vivo in view of the xenograft results. The mimic molecule behaves as DNA-binding antitumor antibiotics with great potential as general anticancer agents and deserves further trials. NSC 710607 represents the result of a design strategy with outstanding potential. This study also identifies the prognostic significance and is likely to translate to other species or systems.
      datePublished:2023-02-13T00:00:00Z
      dateModified:2023-02-13T00:00:00Z
      pageStart:6501
      pageEnd:6511
      sameAs:https://doi.org/10.1007/s00432-023-04604-6
      keywords:
         HCT-116 colorectal carcinoma
         Hollow fiber assay
         Large-scale NCI-60
         Mechanisms of cancer
         Mouse xenografts
         MV-3 human melanoma
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-023-04604-6/MediaObjects/432_2023_4604_Fig6_HTML.png
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:149
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jaroslaw Spychala
            url:http://orcid.org/0000-0002-9965-2425
            affiliation:
                  name:
                  address:
                     name:Poznan, Poland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:149
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:
      address:
         name:Poznan, Poland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jaroslaw Spychala
      url:http://orcid.org/0000-0002-9965-2425
      affiliation:
            name:
            address:
               name:Poznan, Poland
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Poznan, Poland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(160)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.09s.

LINK . SPRINGER . COM {}